The Marlborough, Mass.-based company said that it plans to offer $850 million in 3.45% notes due 2024, $850 million in 3.75% notes due 2026, $850 million in 4% notes due 2029, $750 million in 4.55% notes due 2039 and $1 billion in 4.7% notes due 2049.
Funds will also be used to redeem outstanding notes, including 6% notes due January 2020 and 2.85% notes due May 2020, and to repay amounts outstanding from its $1 billion term loan facility set to mature in August 2019.
Boston Scientific said that it expects the offering to close on February 25.
Earlier this month, the U.S. Federal Trade Commission requested more information about the proposed $4 billion tie-up of BTG and Boston Scientific, but the companies said they still expect the merger to close on schedule in mid-2019.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.